Global Blood Therapeutics (GBT) Set to Announce Earnings on Monday

Defense World · Aug 6, 2022 14:52

Global Blood Therapeutics (NASDAQ:GBT – Get Rating) is scheduled to release its earnings data after the market closes on Monday, August 8th. Analysts expect Global Blood Therapeutics to post earnings of ($1.19) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Global Blood Therapeutics (NASDAQ:GBT – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.03. The company had revenue of $55.20 million for the quarter, compared to the consensus estimate of $56.13 million. Global Blood Therapeutics had a negative net margin of 146.82% and a negative return on equity of 129.74%. The firm's revenue was up 41.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.21) EPS. On average, analysts expect Global Blood Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Get Global Blood Therapeutics alerts:

Global Blood Therapeutics Trading Up 33.0 %

GBT stock opened at $63.84 on Friday. The company has a market capitalization of $4.16 billion, a PE ratio of -13.11 and a beta of 0.83. Global Blood Therapeutics has a 12 month low of $21.65 and a 12 month high of $73.02. The firm's 50-day moving average is $31.23 and its 200 day moving average is $30.75. The company has a debt-to-equity ratio of 4.34, a current ratio of 8.52 and a quick ratio of 7.74.

Insider Buying and Selling

In related news, Director Philip A. Pizzo sold 1,260 shares of Global Blood Therapeutics stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $27.25, for a total value of $34,335.00. Following the completion of the sale, the director now directly owns 9,112 shares in the company, valued at approximately $248,302. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.90% of the stock is owned by company insiders.

Institutional Trading of Global Blood Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Global Blood Therapeutics by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 6,024,262 shares of the company's stock valued at $208,680,000 after acquiring an additional 31,120 shares during the period. State Street Corp lifted its stake in Global Blood Therapeutics by 9.0% during the 1st quarter. State Street Corp now owns 3,456,012 shares of the company's stock valued at $119,716,000 after acquiring an additional 284,877 shares during the period. Goldman Sachs Group Inc. lifted its stake in Global Blood Therapeutics by 48.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,833,720 shares of the company's stock valued at $63,520,000 after acquiring an additional 595,983 shares during the period. Polar Capital Holdings Plc lifted its stake in shares of Global Blood Therapeutics by 19.0% in the 1st quarter. Polar Capital Holdings Plc now owns 1,095,810 shares of the company's stock valued at $37,959,000 after purchasing an additional 175,000 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Global Blood Therapeutics by 26.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 530,693 shares of the company's stock valued at $18,384,000 after purchasing an additional 111,130 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Wedbush set a $74.00 price target on shares of Global Blood Therapeutics in a research note on Monday, June 20th. StockNews.com raised shares of Global Blood Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 5th. Cantor Fitzgerald initiated coverage on shares of Global Blood Therapeutics in a research report on Thursday, April 28th. They issued a "buy" rating and a $75.00 price objective on the stock. Oppenheimer cut their price objective on shares of Global Blood Therapeutics from $86.00 to $71.00 in a research report on Thursday, May 5th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 28th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.40.

About Global Blood Therapeutics

(Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.